Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics in 2019 ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

The FDA has accepted Merck's (NYSE:MRK) supplemental New Drug Application with priority review for its drug Welireg, also ...

Merck MRK will report its first-quarter 2024 earnings on April 24, before market open. The Zacks Consensus Estimate for first ...

Sales of WELIREG increased 63% ... cardiometabolic portfolio through a licensing agreement with Hengrui Pharma. Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 ...

Merck MRK reported its first-quarter 2025 results ... Keytruda, new products like Welireg, Winrevair and Capvaxive and strong performance of the Animal Health segment were partially offset by ...

Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics in 2019 ...